Most Read Articles
29 Jun 2020
At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.

Nonthyroidal illness syndrome, hypothyroidism up risk of mortality, MACE in IHD patients

07 Jul 2020

Nonthyroidal illness syndrome (NTIS) and hypothyroidism appear to increase the risk of all-cause mortality and major adverse cardiac events (MACE) in patients with ischaemic heart disease (IHD), suggests a recent study.

The databases of PubMed, Embase, Scopus, Web of Science, and Cochrane Library were searched from inception through 17 February 2020. Studies were considered eligible if they enrolled IHD patients, compared all-cause mortality and MACE of NTIS and hypothyroidism with those of euthyroidism, and provided adequate information for meta-analysis.

The investigators also extracted relevant information and numerical data for methodological assessment and meta-analysis.

Twenty-three studies met the eligibility criteria. The IHD population with NTIS had a higher risk of all-cause mortality (hazard ratio [HR], 2.61, 95 percent confidence interval [CI], 1.89–3.59) and MACE (HR, 2.22, 95 percent CI, 1.71–2.89) than that without. Similarly, the IHD population with hypothyroidism were at higher risk of all-cause mortality (HR, 1.47, 95 percent CI, 1.10–1.97) and MACE (HR, 1.53, 95 percent CI, 1.19–1.97) than that without.

Subgroup analysis revealed a significantly increased risk of all-cause mortality (HR, 3.30, 95 percent CI, 2.43–4.48) and MACE (HR, 2.19, 95 percent CI, 1.45–3.30) in the acute coronary syndrome (ACS) subpopulation with NTIS. Likewise, the ACS subpopulation with hypothyroidism showed a higher risk of all-cause mortality (HR, 1.67, 95 percent CI, 1.17–2.39).

“Future research is required to provide evidence of the causal relationship and to elucidate whether normalizing thyroid function parameters can improve prognosis,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jun 2020
At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.